Alzheon, Inc.

Alzheon, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com

Company Details

Employees
33
Founded
-
Address
111 Speen Street, Suite 306, Framingham,ma 01701,united States
Phone
(857) 214-7242
Email
jo****@****doe.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Framingham, MA
Looking for a particular Alzheon, Inc. employee's phone or email?

Alzheon, Inc. Questions

News

Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease - Yahoo Finance

Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease Yahoo Finance

Alzheon’s Alzheimer’s pill fails in Phase III trial - Clinical Trials Arena

Alzheon’s Alzheimer’s pill fails in Phase III trial Clinical Trials Arena

Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate - NeurologyLive

Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate NeurologyLive

Alzheon Alzheimer's drug knocked down in pivotal APOLLOE4 bout - Fierce Biotech

Alzheon Alzheimer's drug knocked down in pivotal APOLLOE4 bout Fierce Biotech

Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025 - Business Wire

Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025 Business Wire

Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study - MedCity News

Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study MedCity News

Alzheon Appoints Muneer A. Satter to Board of Directors - citybiz

Alzheon Appoints Muneer A. Satter to Board of Directors citybiz

Alzheon Alzheimer’s Pill Misses the Mark in Phase 3 Trial, Hints at Benefit in MCI - Being Patient

Alzheon Alzheimer’s Pill Misses the Mark in Phase 3 Trial, Hints at Benefit in MCI Being Patient

AD/PD 2025: Alzheon’s ALZ-801 shows promise for MCI but missed in mild Alzheimer’s - Clinical Trials Arena

AD/PD 2025: Alzheon’s ALZ-801 shows promise for MCI but missed in mild Alzheimer’s Clinical Trials Arena

Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025 - Business Wire

Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025 Business Wire

Oral Treatment Shows Promise in Combating Alzheimer Disease - Pharmacy Times

Oral Treatment Shows Promise in Combating Alzheimer Disease Pharmacy Times

Alzheon’s Oral Alzheimer’s Drug Shows Safety and Promise for APOE4/4 - Inside Precision Medicine

Alzheon’s Oral Alzheimer’s Drug Shows Safety and Promise for APOE4/4 Inside Precision Medicine

Alzheon zeroes in on subgroup data after Alzheimer's study misses mark - FirstWord Pharma

Alzheon zeroes in on subgroup data after Alzheimer's study misses mark FirstWord Pharma

Alzheon Alzheimer's hopes dented by trial readout - pharmaphorum

Alzheon Alzheimer's hopes dented by trial readout pharmaphorum

Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon - Business Wire

Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon Business Wire

Early Biomarker Evaluation and Cognitive Stabilization in Alzheimer Treatment: Martin Tolar, MD, PhD - NeurologyLive

Early Biomarker Evaluation and Cognitive Stabilization in Alzheimer Treatment: Martin Tolar, MD, PhD NeurologyLive

Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors - Business Wire

Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors Business Wire

AAN 2024: Biomarker data shows promise for Alzheon’s oral anti-amyloid drug - Clinical Trials Arena

AAN 2024: Biomarker data shows promise for Alzheon’s oral anti-amyloid drug Clinical Trials Arena

Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease - Business Wire

Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease Business Wire

AD/PD 2025: Alzheon’s ALZ-801 shows promise for MCI but missed in mild Alzheimer’s - Yahoo Finance

AD/PD 2025: Alzheon’s ALZ-801 shows promise for MCI but missed in mild Alzheimer’s Yahoo Finance

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing - Genetic Engineering and Biotechnology News

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing Genetic Engineering and Biotechnology News

Alzheon’s amyloid-targeting pill fails another Phase 3 study in Alzheimer’s - Endpoints News

Alzheon’s amyloid-targeting pill fails another Phase 3 study in Alzheimer’s Endpoints News

Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer - citybiz

Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer citybiz

ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s... - Alzheimer's News Today

ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s... Alzheimer's News Today

Alzheon Appoints Gino Santini to Board of Directors - citybiz

Alzheon Appoints Gino Santini to Board of Directors citybiz

Alzheon secures NIA grant for Alzheimer’s disease trial - Clinical Trials Arena

Alzheon secures NIA grant for Alzheimer’s disease trial Clinical Trials Arena

No IPO? No problem: Alzheon bags $47M NIH grant to bankroll Alzheimer's trial - Fierce Biotech

No IPO? No problem: Alzheon bags $47M NIH grant to bankroll Alzheimer's trial Fierce Biotech

TRIALS UPDATE: The Latest Alzheimer’s Clinical Trial News (2025.01) - Being Patient

TRIALS UPDATE: The Latest Alzheimer’s Clinical Trial News (2025.01) Being Patient

A Pill to Slow Down Alzheimer’s Is as Little as a Year Away - Being Patient

A Pill to Slow Down Alzheimer’s Is as Little as a Year Away Being Patient

Longevity Startups Are Getting Funding, But Not As Fast As We’re Aging - Crunchbase News

Longevity Startups Are Getting Funding, But Not As Fast As We’re Aging Crunchbase News

Alzheon relaunches IPO plans - - Global Venturing

Alzheon relaunches IPO plans - Global Venturing

What Happened? Alzheon Leaves IPO on the Table for the Second Time - BioSpace

What Happened? Alzheon Leaves IPO on the Table for the Second Time BioSpace

Alzheon approaches public markets - - Global Venturing

Alzheon approaches public markets - Global Venturing

Alzheon CEO calls out Biogen, says his firm will be 1st to Alzheimer’s finish line - BioPharma Dive

Alzheon CEO calls out Biogen, says his firm will be 1st to Alzheimer’s finish line BioPharma Dive

Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon - PMLiVE

Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon PMLiVE

Top Alzheon, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant